We are live on ! Find out more
BNTX icon

BioNTech

109 hedge funds and large institutions have $1.78B invested in BioNTech in 2020 Q2 according to their latest regulatory filings, with 78 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,200% more first-time investments, than exits

New positions opened: 78 | Existing positions closed: 6

363% more capital invested

Capital invested by funds: $384M → $1.78B (+$1.39B)

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

195% more funds holding

Funds holding: 37109 (+72)

186% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 7

31% more call options, than puts

Call options by funds: $33.4M | Put options by funds: $25.4M

8.73% more ownership

Funds ownership: 2.92%11.65% (+8.7%)

Holders
109
Holders Change
+72
Holders Change %
+194.59%
% of All Funds
2.23%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.06%
New
78
Increased
20
Reduced
7
Closed
6
Calls
$33.4M
Puts
$25.4M
Net Calls
+$7.98M
Net Calls Change
+$7.98M

BNTX Hedge Fund Activity: Q2 2020 in Review

109 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q2 2020, worth a combined $1.78B — up 363% from $384M a quarter earlier.

Buyers outnumbered sellers: 78 funds opened new BNTX positions and 6 closed out — a net gain of 72 holders — while 20 added to existing stakes and 7 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $473M. The largest seller was Artal Group, cutting an estimated $11.4M.

  • 109 institutional investors held BioNTech (BNTX) as of Q2 2020, up from 37 in Q1 2020.
  • Funds reported $1.78B of BioNTech stock for Q2 2020, up 363% quarter-over-quarter.
  • 78 funds opened new BioNTech positions in Q2 2020 and 6 closed out, a net change of +72 holders.
  • The largest BioNTech buyer in Q2 2020 was Fidelity Investments, an estimated $473M added.
  • The largest BioNTech seller in Q2 2020 was Artal Group, an estimated $11.4M sold.

Based on aggregated 13F filings for Q2 2020.